Regional trends in the use of steroids and favipiravir for COVID-19 treatment

Article Infectious Diseases

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

Mohammad Bosaeed et al.

Summary: Favipiravir treatment does not reduce the time to viral clearance in mild COVID-19 cases.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Infectious Diseases

Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan

Shinya Tsuzuki et al.

Summary: This study evaluated the effectiveness of favipiravir on nonsevere, early-stage COVID-19 patients using a nationwide registry. The results showed that favipiravir did not have a positive effect on the clinical outcome of these patients, suggesting that it is not an essential drug for COVID-19 treatment.

INFECTIOUS DISEASES AND THERAPY (2022)

Add to Collection

Review Public, Environmental & Occupational Health

Evaluation of the representativeness of data in the COVID-19 Registry Japan during the first six waves of the epidemic

Kayoko Hayakawa et al.

Summary: The representativeness of COVIREGI-JP data was examined by comparing it with open-source national data. The study found that patients in COVIREGI-JP represented 1% of the total COVID-19 cases according to national data, and the proportion tended to decline after the beginning of the epidemic. Additionally, the case fatality rates in COVIREGI-JP tended to be higher than those in the national data.

GLOBAL HEALTH & MEDICINE (2022)

Add to Collection

Article Immunology

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko et al.

Summary: In May 2020, AVIFAVIR, an RNA polymerase inhibitor, was granted fast-track marketing authorization by the Russian Ministry of Health for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR demonstrated a 62.5% viral clearance rate within 4 days for SARS-CoV-2 patients and was shown to be safe and well-tolerated.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan

Nobuaki Matsunaga et al.

Summary: This study in Japan examined hospitalized patients with COVID-19, finding that they are typically middle-aged males with close contact to confirmed or suspected cases. The most common comorbidities were hypertension and diabetes. Most patients admitted were nonsevere cases, with a majority not requiring oxygen support during hospitalization.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs

Alessandra Bartoli et al.

Summary: There is currently no specific therapy for COVID-19 disease, and clinical studies have methodological limitations. Different categories of drugs have varying efficacy at different stages of the disease, emphasizing the need for further well-designed clinical trials to establish a standard of care for COVID-19.

INTERNAL AND EMERGENCY MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome

Koichiro Suemori et al.

Summary: Favipiravir has shown effectiveness in treating patients with Severe fever with thrombocytopenia syndrome (SFTS), with a lower 28-day mortality rate compared to previous studies. Although adverse events were observed in some patients, the drug was generally well tolerated and showed potential in improving clinical symptoms and reducing viral load in SFTS patients.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Add to Collection

Article Infectious Diseases

Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial

Masaharu Shinkai et al.

Summary: The study found that favipiravir may be an option for treating moderate COVID-19 pneumonia, with better effects in patients with obesity or coexisting conditions. However, the risk of adverse events, including hyperuricemia, should be carefully considered when using favipiravir.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection

Article Infectious Diseases